Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Invested Capital (2016 - 2025)

ImmunityBio (IBRX) has disclosed Invested Capital for 13 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 97.77% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, down 97.77% year-over-year, with the annual reading at $4.5 million for FY2025, 97.77% down from the prior year.
  • Invested Capital for Q4 2025 was $4.5 million at ImmunityBio, up from -$388.0 million in the prior quarter.
  • The five-year high for Invested Capital was $203.4 million in Q4 2024, with the low at -$645.2 million in Q2 2023.
  • Average Invested Capital over 5 years is -$287.0 million, with a median of -$362.8 million recorded in 2022.
  • The sharpest move saw Invested Capital plummeted 954.3% in 2021, then surged 137.64% in 2024.
  • Over 5 years, Invested Capital stood at -$243.9 million in 2021, then grew by 14.5% to -$208.5 million in 2022, then plummeted by 159.07% to -$540.3 million in 2023, then soared by 137.64% to $203.4 million in 2024, then crashed by 97.77% to $4.5 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $4.5 million, -$388.0 million, and -$414.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.